MK-7

MK-7 (menaquinone-7) is a long-chain vitamin K2 homolog that functions as a cofactor for γ-glutamyl carboxylase, enabling γ-carboxylation of vitamin K-dependent proteins (VKDPs) including osteocalcin and matrix Gla protein to regulate calcium deposition in bone and vasculature. In postmenopausal women supplementing 180 μg/day for approximately three years, MK-7 significantly inhibited bone loss and maintained bone strength, while demonstrating a plasma half-life of approximately 56 hours—roughly seven-fold longer than vitamin K1—producing sustained VKDP carboxylation superior to shorter-chain menaquinones.

Origin & History

MK-7 is a long-chain menaquinone (vitamin K2 homolog) produced naturally through bacterial fermentation, most notably in natto, a traditional Japanese food made from soybeans fermented with Bacillus subtilis, which has been consumed in Japan for over a millennium. Commercial MK-7 is primarily derived from controlled fermentation of Bacillus licheniformis or Bacillus subtilis, with the purified compound isolated from fermentation broths and processed into crystalline supplement-grade material exceeding 96% purity in leading branded forms. Synthetic MK-7 is also manufactured via chemical synthesis, though fermentation-derived forms remain the industry standard due to their superior all-trans isomer profile and established clinical validation.

Historical & Cultural Context

Natto, the primary traditional source of MK-7, has been consumed in Japan for over 1,000 years, with historical records referencing its production during the Heian period (794–1185 CE) and its association with regional longevity in Japanese populations—particularly in eastern Japan where natto consumption is highest and cardiovascular disease rates have historically been comparatively lower. In Japanese folk medicine and dietary tradition, natto was valued for its strengthening properties and digestive benefits, though the specific identification of menaquinones as bioactive constituents awaited modern biochemical analysis in the latter twentieth century. The scientific isolation and characterization of MK-7 as a distinct, pharmacologically superior vitamin K2 homolog emerged from nutritional epidemiology research in the 1990s and 2000s, notably catalyzed by investigations into the 'natto paradox'—the observation that Japanese populations consuming natto showed lower rates of hip fracture and arterial calcification despite similar calcium intakes to Western populations. Modern commercial production via Bacillus licheniformis fermentation was developed to replicate the biological activity of natto-derived MK-7 in a standardized, purified supplement form, bridging traditional fermented food heritage with contemporary nutraceutical science.

Health Benefits

- **Arterial Calcification Prevention**: MK-7 activates matrix Gla protein (MGP) through γ-carboxylation, enabling MGP to chelate calcium ions in arterial walls and prevent vascular smooth muscle calcification; ten published MenaQ7® studies document measurable reductions in markers of arterial stiffening.
- **Bone Mineral Density Support**: By carboxylating osteocalcin (OC), MK-7 ensures proper calcium binding and incorporation into the bone matrix; supplementation at 90–180 μg/day has been shown to promote OC carboxylation in postmenopausal women at doses where shorter-chain MK-4 at equivalent microgram doses proved ineffective.
- **Osteoblast Stimulation and Osteoclast Suppression**: MK-7 directly promotes osteoblastogenesis and suppresses osteoclastogenesis via NF-κB pathway inhibition, shifting bone remodeling balance toward net bone formation independent of its cofactor role.
- **Superior Bioavailability and Sustained Tissue Delivery**: The seven-isoprene side chain of MK-7 confers high lipophilicity that facilitates association with LDL particles, enabling preferential delivery to extrahepatic tissues including bone and vasculature; peak serum levels are approximately ten-fold higher than vitamin K1 and the 56-hour half-life ensures continuous tissue saturation between daily doses.
- **Anti-Inflammatory Modulation**: MK-7 modulates NF-κB, PI3K/AKT, MAP kinase, and JAK/STAT signaling pathways, reducing pro-inflammatory cytokine expression; these pathways collectively contribute to its observed benefits in vascular and bone tissue inflammation.
- **Metabolic and Hormonal Regulation**: MK-7 undergoes partial conversion to MK-4 in peripheral tissues, which activates the steroid and xenobiotic receptor (SXR/PXR) to upregulate genes involved in bone formation and lipid metabolism, providing a secondary hormonal mechanism beyond direct VKDP carboxylation.
- **Potential Anti-Cancer Activity**: Preclinical studies demonstrate MK-7 induces cell-cycle arrest, autophagy, and apoptosis in cancer cell lines through modulation of PI3K/AKT and NF-κB pathways, though human clinical evidence for oncological applications remains preliminary and should not be extrapolated to therapeutic claims.

How It Works

MK-7 functions primarily as an obligate cofactor for the microsomal enzyme γ-glutamyl carboxylase (GGCX), which catalyzes the post-translational γ-carboxylation of glutamate residues on vitamin K-dependent proteins (VKDPs); this reaction converts undercarboxylated osteocalcin and matrix Gla protein into their biologically active forms capable of binding calcium with high affinity, directing mineral deposition to bone while simultaneously preventing pathological calcification in arterial intima and media. The seven-isoprene side chain distinguishes MK-7 from shorter menaquinones by dramatically increasing molecular lipophilicity, enabling incorporation into LDL particles for systemic circulation and sustained extrahepatic delivery to osteoblasts and vascular smooth muscle cells where VKDPs are most critically expressed. In bone tissue, MK-7 additionally stimulates osteoblast differentiation and proliferation while suppressing osteoclast formation through direct inhibition of NF-κB signaling, and its partial tissue conversion to MK-4 activates the nuclear steroid and xenobiotic receptor (SXR/PXR), inducing transcription of bone formation genes including alkaline phosphatase and collagen type I. Anti-inflammatory and anti-proliferative effects are mediated through concurrent suppression of NF-κB-driven cytokine transcription, attenuation of PI3K/AKT pro-survival signaling, and modulation of MAP kinase and JAK/STAT cascades, positioning MK-7 as a pleiotropic signaling molecule beyond its classical coagulation and mineralization roles.

Scientific Research

The clinical evidence base for MK-7 is moderate and growing, anchored by several randomized controlled trials of reasonable quality but limited by relatively small sample sizes and the predominance of trials using branded MenaQ7® formulations, which may limit generalizability. The most cited bone health trial enrolled postmenopausal women receiving 180 μg/day MK-7 over approximately three years and demonstrated statistically significant inhibition of bone loss with maintenance of bone strength parameters; MenaQ7® has accumulated 22 published clinical trials across bone and vascular endpoints as of recent reports, including 10 studies specifically documenting arterial stiffness benefits. Pharmacokinetic comparisons consistently confirm MK-7's superiority over vitamin K1 and MK-4 in achieving sustained serum elevation—approximately ten-fold higher peak concentrations than K1 and a 56-hour versus 7.5-hour half-life—providing mechanistic confidence that underpins the clinical findings. However, many trials lack published full sample size disclosures in summaries, head-to-head comparator arms are sparse, and independent replication outside branded ingredient research remains limited, warranting cautious interpretation and recognition that large-scale, independently funded RCTs are still needed.

Clinical Summary

The most clinically significant MK-7 trial investigated 180 μg/day supplementation in postmenopausal women over approximately three years, with outcomes including bone mineral density, osteocalcin carboxylation status, and bone strength indices; results showed significant inhibition of age-related bone loss and preservation of bone strength, with carboxylation benefits evident at 90–180 μg/day where equivalent microgram doses of MK-4 failed to achieve meaningful OC activation. Vascular outcomes have been assessed in ten MenaQ7®-specific studies measuring arterial stiffness via pulse wave velocity and related hemodynamic indices, with consistent trends toward reduced arterial stiffening in supplemented groups, though precise effect sizes and confidence intervals are not uniformly reported in available summaries. A five-month rat model study demonstrated prevention of bone mineral density loss and significant improvement in bone strength parameters, corroborating the human data mechanistically. Overall confidence in MK-7 for bone and vascular calcification endpoints is moderate-to-good for the specific outcomes studied, with the body of evidence most robust for osteocalcin carboxylation as a surrogate biomarker and weakest for hard clinical endpoints such as fracture incidence or cardiovascular events.

Nutritional Profile

MK-7 is a pure lipophilic compound (molecular weight 649.0 g/mol) rather than a whole-food matrix ingredient; as an isolated supplement it contributes negligible macronutrients or micronutrients beyond the menaquinone molecule itself. At the nutritional dose of 90–180 μg/day, MK-7 provides no caloric value and functions exclusively as a micronutrient cofactor. In its native food source natto, MK-7 coexists with significant protein (~18 g/100 g), dietary fiber (~5 g/100 g), isoflavones (genistein, daidzein at ~60 mg/100 g), nattokinase enzyme, and a full complement of B vitamins including riboflavin and B6, which may contribute synergistic cardiovascular benefits in whole-food consumption. Bioavailability of supplement-form MK-7 is substantially higher than food-matrix vitamin K1, with approximately ten-fold greater peak plasma concentration achieved and a half-life of ~56 hours enabling continuous tissue saturation; fat co-ingestion is required for optimal micellar solubilization and lymphatic absorption via chylomicrons, subsequently redistributing via LDL for extrahepatic tissue delivery.

Preparation & Dosage

- **Fermented natto-derived MK-7**: Traditional Japanese dietary source providing 100–1000 μg per 100 g serving; not standardized for supplement use but represents the most bioavailable natural matrix form.
- **Branded fermented extract (MenaQ7®, >96% all-trans MK-7)**: 90–180 μg/day for nutritional bone and vascular benefits; derived from Bacillus licheniformis fermentation with documented clinical validation across 22 trials.
- **Synthetic MK-7 capsules/softgels**: 100–200 μg/day; verify all-trans isomer content >90% on certificate of analysis, as cis-MK-7 (biologically inactive) can comprise up to 1.7% of lower-quality preparations.
- **Effective clinical dose range**: 90–180 μg/day for osteocalcin carboxylation and arterial MGP activation; pharmacological doses up to 45 mg/day have been used in MK-4 equivalent research but are not standard for MK-7 specifically.
- **Timing and administration**: Take with a fat-containing meal to maximize absorption given high lipophilicity and fat-soluble nature; once-daily dosing is sufficient given the 56-hour plasma half-life.
- **Stability note**: MK-7 degrades significantly when formulated alongside certain minerals (e.g., magnesium, calcium) in combination supplements—some preparations lose up to 50% potency within one month; choose formulations with separate mineral compartmentalization or independently verified potency at expiry.
- **Standardization**: High-quality supplements should specify ≥90% all-trans-MK-7 content; third-party assay verification is recommended given documented label inaccuracies (55–117% of claimed content in market surveys).

Synergy & Pairings

MK-7 demonstrates well-characterized synergy with vitamin D3 (cholecalciferol), as vitamin D3 upregulates osteocalcin gene transcription and increases the production of undercarboxylated osteocalcin substrate, while MK-7 provides the enzymatic cofactor activity required to carboxylate and activate that substrate—the combination produces greater improvements in bone mineral density and osteocalcin carboxylation than either compound alone, and this pairing is supported by both mechanistic rationale and clinical co-supplementation data. Calcium co-supplementation with MK-7 is physiologically rational, as MK-7 activates the calcium-regulatory VKDPs (osteocalcin and MGP) that direct supplemental calcium toward bone mineralization rather than arterial deposition, effectively acting as a 'calcium chaperone' that reduces the calcification risk associated with high-dose calcium supplementation. Magnesium supports MK-7 activity indirectly through its role in vitamin D activation (magnesium-dependent hydroxylation steps) and as a cofactor in osteoblast function; however, direct formulation of MK-7 with magnesium in the same tablet should be avoided due to documented degradation of MK-7 in the presence of mineral excipients.

Safety & Interactions

MK-7 is well-tolerated at nutritional doses of 90–180 μg/day with no clinically significant adverse effects reported in human trials to date; the compound has been consumed as a dietary component in natto for centuries without documented toxicity at food-level exposures. The most critical drug interaction is with vitamin K antagonist anticoagulants, particularly warfarin (coumadin) and acenocoumarol—MK-7 supplementation at doses as low as 100 μg/day can measurably alter prothrombin time and INR in anticoagulated patients, potentially reducing anticoagulant efficacy and increasing thrombotic risk; patients on these medications must not supplement MK-7 without hematological monitoring and physician guidance. MK-7 should be used with caution in individuals with hypercoagulable states, clotting disorders, or those receiving direct oral anticoagulants (DOACs) such as rivaroxaban or apixaban, as the interaction profile with these newer agents has not been fully characterized. Supplement stability in multi-ingredient formulations containing divalent mineral cations (calcium, magnesium, iron) is a practical safety consideration—degradation products and reduced potency may alter expected dosing outcomes; pregnancy and lactation guidance follows general vitamin K2 safety precedent (considered safe at nutritional doses), but high-dose supplementation during pregnancy should be undertaken only under medical supervision given limited specific gestational data.